Pharma

Your Article Summary

See Latest Articles

AstraZeneca and Abbott submit New Drug Application to the FDA for CERTRIAD, an investigational treatment for mixed dyslipidemia
AstraZeneca, 06/05/09

AstraZeneca and Abbott announced that the companies have submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL cholesterol, high triglycerides and low HDL-cholesterol. The NDA submission for this investigational compound, containing the active ingredients of CRESTOR and TRILIPIX,is supported by data from multiple studies, including efficacy and safety studies with the 5mg, 10mg and 20mg doses of rosuvastatin combined with fenofibric acid.

Today in Regulatory Issues...keeping you current

Receive free subspecialty "5-minute updates" via email

Two Delivery Systems Win Baldrige Award
HealthDataManagement, 12/18/09

Advisory Committee briefing materials for CRESTOR sNDA available on US FDA web site
AstraZeneca, 12/15/09

Sixteen Fired for Records Snooping
HealthDataManagement, 12/09/09

 See all of Regulatory Issues